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Abstract
Introduction. The present investigation is pursued to study the possible association of –463G>A and –129G>A poly-
morphism in MPO gene and assessment of plasma MPO levels with the risk of developing coronary artery disease.
Material and methods. A total of 200 angiographically documented CAD patients and 200 age, gender ethnicity 
matched healthy controls were recruited for the study. Plasma MPO levels were assessed using enzyme-linked immu-
nosorbent assay (ELISA) kit and genotypes were determined by PCR-RFLP technique.
Results. The MPO levels were found to be significantly increased in CAD patients when compared with controls (p < 0.04) 
but there were no significant effect of –463G>A gene polymorphism on MPO levels. A significant association of –463G>A 
polymorphism was observed with coronary artery disease. The frequency of recessive genotype “AA” at –463 promoter 
site was considerably lesser in patients (4%) relative to controls (11%) (odds ratio [OR] = 0.3371, 95% confidence interval 
[CI] 0.1463–0.7766, p = 0.012). However we did not find significant association of –129G>A polymorphism with CAD. 
Additionally, haplotype analysis revealed that single nucleotide polymorphisms (SNP) 1 of AA genotype and SNP 2 of GG 
genotype showed significant protective effect with disease (OR = 0.64; 95% CI [0.42–0.96], p = 0.032).
Conclusion. The results revealed that –463G>A polymorphism in the MPO gene lowers the CAD related condition in 
patients by down regulating serum MPO concentration, which is known to aggravate the atherosclerotic events observed 
in CAD.
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Introduction
Coronary artery disease (CAD) surfaced as a multifactorial 
disease with acquired and inherited components and offers 
significant economic burden to developing countries like 
India [1]. The prevalence of CAD in Indian subcontinent is 
typically manifested between the age group of 20–40 years 
and 20–45 years respectively in young men and women 
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[2]. CAD is characterized by atherosclerosis — a chronic 
inflammatory process involving accumulation of lipoprotein 
particles in the intima of the coronary artery and deposition 
of fibrous plaque containing smooth muscle cells, lipids, 
fibrous tissue and extra cellular matrix proteins [3, 4]. 
Accumulation of atheroma can limit blood flow to the my-
ocardium resulting in ischemic discomfort and progressi-
vely leading to myocardial infarction (MI) [5]. Pioneering 
studies revealed the pivotal role of myeloperoxidase (MPO) 
in clinical presentation of atherosclerosis and development 
of coronary artery disease (CAD) [6]. MPO is an enzyme 
produced in the bone marrow during myeloid differentiation 
which accumulates in neutrophils and monocytes before 
their entry in circulation and is gradually released during 
inflammation upon leukocytes activation and degranulation 
[7]. Despite its antimicrobial activity, MPO has a strong pro-
-inflammatory feature that promotes tissue injury through 
oxidative damage at inflammatory site [8]. MPO plays an 
important role in the diagnosis and prognosis of CAD and 
elevated MPO levels frequently form the predictive marker 
for cardiovascular diseases [9].
MPO is a heme protein encoded by a single gene appro-
ximately 11kb located on chromosome 17q23.1 composed 
of 11 introns and 12 exons [10]. Elevated levels of MPO has 
been demonstrated in response to significant polymorphi-
sm like, –463G>A, –129G>A, –V53F, –A332V, –638C>A 
locussed at the promoter region of the MPO gene [11].
A prominent functional polymorphism involving G to 
A base exchange at –463 (rs2333227) located in the pro-
moter region was documented to positively elevate MPO 
transcriptional activity by reversible binding of SP1 trans-
cription factor [12]. In addition, the clinical impact of –463G 
allele has been suggested in several diseases wherein 
MPO serum concentration were relatively higher to healthy 
controls activity was significantly elevated [13, 14]. Studies 
have shown that in myeloid cell lines –463G>A obliterates 
the binding site for SP1 that results in decreased the ex-
pression of MPO enzyme in the cell [12].
Another relevant polymorphism i.e., G>A substitution 
located at promoter position –129 upstream alters the 
transcription start site by abolishing SP1 binding efficien-
cy [11, 15]. According to documented medical literature, 
there are no published reports mentioning the MPO gene 
polymorphisms in relation to CAD especially in south Indian 
population. Hence the present study was aimed to evaluate 
the association of MPO gene (–463G>A and –129G>A) in 
clinical presentation of CAD.
Materials and methods
The study group included 200 patients (20–40 yrs.) with 
angiographically diagnosed clinical presentation of acute 
myocardial infarction admitted at the Department of Car-
diology, Gandhi Hospital and Nizams Institute of Medical 
Sciences, Hyderabad, India. Patients presenting with syste-
mic inflammatory disease, liver disease, cardiomyopathy, 
malignancy or any other heart diseases were excluded 
from the study. The control group consisted of 200 age, 
gender and ethnicity matched healthy individuals with no 
clinical or family history of CAD or clinical symptoms of any 
other systemic disease. The epidemiological variables like 
age, gender, nativity, occupation, life style habits, family 
history and clinical symptoms were recorded in the form of 
structured questionnaire. The study was approved from the 
institutional ethics committee for biomedical research. An 
informed consent was taken from the patients prior to the 
study and the objectives of the study were clearly explained.
Overnight fasting venous blood (5 ml) was drawn 
from fasting subjects with 0.1% EDTA. Blood from each 
subject was assayed for serum concentrations of total 
cholesterol (TC), triglycerides (TG), LDL-cholesterol (LDL-C), 
HDL-cholesterol (HDL-C), and VLDL-cholesterol (VLDL-C) 
by commercially available assay kits (ERBA, diagnostics, 
Mannheim GMBH, Germany) using CHEM-7 semi auto 
analyzer (ERBA Mannheim ,Germany). Further sample was 
centrifuged (2,000 rpm for 15 min) and stored in micro-
-tubes –80°C for genomic DNA extraction by salting out 
procedure (TKM) [16].
MPO measurement
Plasma MPO levels were assessed using enzyme-linked 
immunosorbent assay (ELISA) kit (Hycult biotech, Catalog 
number HK324, The Netherlands) based on the sandwich 
principle and the detection range of the samples was 0.4 to 
100 ng/ml. The absorbance of the samples was measured 
by using a microplate reader at 450 nm.
Analysis of myeloperoxidase –463G/A and –129G>A 
gene polymorphisms: the –463G>A and –129G>A poly-
morphic sites were analyzed using PCR and RFLP technique 
(Table 1).
Statistical analysis
Hardy-Weinberg equilibrium was tested for the MPO gene 
polymorphism and the association between genotypes and 
CAD was examined by odds ratio and chi-square analysis 
with threshold confidence interval (CI) of 95% using open 
EPI6 software (Open Epi Version 2.3.1, Department of Epi-
demiology, Rollins School of Public Health, Emory Universi-
ty, Atlanta, GA 30322, USA). The demographic and clinical 
data were expressed as mean ± standard deviation (SD) 
value and p values were calculated using Students’ paired 
t-test. Haplotype association of MPO gene polymorphism 
and CAD was examined by odds ratio with 95% CI employing 
single nucleotide polymorphisms (SNP) stats web server 
[17]. The coefficient (D’) of pairwise linkage disequilibrium 
(LD) between the SNPs was calculated using the software 
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haploview version 4,2 ref. All the p values were two sided, 
and the level of significance was considered at p < 0.05.
Results
The demographic and clinical data of the CAD patients and 
controls is summarized in Table 2. The mean age of CAD 
Table 1. Sequences of primers and digestion fragment lengths used for myeloperoxidase (MPO) genotyping
MPO promoter Primers Restriction enzyme Genotype (characterized by fragments in bp)
–463G>A F:5’CGGTATAGGCACACAATGGTGAG3’ 
R:5’ GCAATGGTTCAAGCGATTCTTC 3’
AciI GG(168,121,61) 
GA(289,168,121,61) 
AA(289,61)
–129G>A F:5’CCTCCACAGCTCACCTGATAT3’ 
R:5’ CGCTTGAACCATTGCACATCA3’
ApaI GG(278) 
GA(278,124,154) 
AA(124,154)
patients was 37.0 years and that for controls was 36.0 
years. The differences between CAD patients and control 
subjects were statistically significant in all measures of 
established risk factors such as hypertension, smoking, 
alcohol and family history of CAD. The clinical data on 
TC, LDL-C and TG was found to be significantly elevated 
in patients than in healthy controls (p < 0.001) on the 
contrary HDL-C was higher in controls than their patient 
counterparts (p < 0.001). Myeloperoxidase levels were 
found to be significantly increased in patients when com-
pared with controls (p < 0.04, Table 3) and there was no 
statistically significant difference found in distribution of 
–463G>A gene polymorphism in patients when compared 
with controls (p = 0.7, Table 4).The frequency distribution 
of different genotypes in cases and controls are shown 
in Table 5 and 6. A significant association was observed 
Table 2. The demographic and clinical characteristics of coronary artery disease (CAD) patients and controls
Characteristics CAD patients Controls p value
Mean age 37.0 ± 3.6 36.0 ± 5.8 NS
Male:female 161:39 159:41 NS
BMI [kg/m2] 25.02 ± 1.40 23.54 ± 1.29 NS
TC [mg/dl] 194.14 ± 40.5 155.23 ± 20.6 < 0.001*
LDL [mg/dl] 133.8 ± 42.4 90.14 ± 21.9 < 0.001*
HDL [mg/dl] 31.66 ± 9.53 42.67 ± 14.15 < 0.001*
TG [mg/dl] 139.34 ± 29.58 112.85 ± 33.79 < 0.001*
SBP [mm Hg] 129.28 ± 9.48 112.66 ± 9.06 < 0.001*
DBP [mm Hg] 84.63 ± 8.42 79.8 ± 6.58 < 0.001*
Smoking 85 (42.5%) 44 (22%) < 0.001*
Alcoholism 73 (36.5%) 26 (13%) <0.001*
Family history 58 (29%) 3 (1.5%) <0.001*
*p values were calculated using Students’ paired t-test; NS — not significant; BMI — body mass index; TC — total cholesterol; LDL — low-density lipoprotein; HDL — high-density lipoprotein; TG — triglycerides; 
SBP — systolic blood pressure; DBP — diastolic blood pressure
Table 3. Plasma myeloperoxidase (MPO) levels in coronary artery 
disease (CAD) patients and controls
Subjects (n= 200) MPO ng/ml 
Mean ± SD
p value
CAD cases 44.5 ± 21.2 < 0.04*
Healthy controls 28.3 ± 18.4
*p < 0.05; SD — standard deviation
Table 4. Distribution of plasma myeloperoxidase (MPO) levels in relation to MPO –463G>A gene polymorphism
MPO levels (ng/ml) MPO genotype –463G>A ANOVA
Healthy controls GG (n = 103) GA (n = 75) AA (n = 22)
42.3 ± 19.6 34.5 ± 21.7 28.4 ± 12.3 < 0.01
CAD cases GG (n = 108) GA (n = 84) AA (n = 08) 0.7
43.38 ± 20.3 45.6 ± 21.4 42.20 ± 28.6
CAD — coronary artery disease
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for genetic variation at MPO (–463G>A) and CAD. The GG 
genotype was found to be most frequent in both cases 
(54%) and controls (51.5%) and the frequency of AA geno-
type was 4% among cases while 11% among the controls. 
The recessive genotype was significantly more frequent in 
the CAD patients than in controls, implying lower levels of 
serum MPO concentrations (odds ratio [OR] = 0.3371, 95% 
CI [0.1463–0.7766], p = 0.012).
In further analysis we found, no significant association 
of MPO (–129G>A) with CAD. The frequencies of ‘GG’ 
(51.5%), ‘GA’ (40%) and ‘AA’ (8.5%) genotype were not 
significantly different in cases with reference to controls 
GG (56%), GA (37.5%) and AA (6.5%). We further performed 
haplotype analysis by considering SNP 1(–463G>A) and 
SNP 2 (–129G>A) for which we did not find any significant 
association of either genotype/alleles of [SNP 1 GG/G and 
SNP 2 AA/A; SNP 1 AA/A and SNP 2 AA/A], whereas on 
the other hand AA/A of SNP 1 and GG/G of SNP 2 showed 
significant protective effect with disease (OR = 0.64, 95% 
CI [0.42–0.96], p = 0.032). Linkage disequilibrium analysis 
(LD), defined by the delta coefficient (D’), was determined 
for both patients and controls for two SNPs, –463G>A and 
–129G>A. No linkage disequilibrium was observed between 
the two SNP polymorphisms (Figure 1).
Discussion
In recent years, several studies have confirmed that eleva-
ted concentrations of MPO are independently associated 
with increased risk of CAD [18–20]. Both the polymorphic 
variants MPO –463G>A and MPO –129G>A are located 
upstream of the translation initiation codon of MPO gene. 
These two variants have been reported to disrupt the 
SP1-binding site in an Alu hormone-responsive element and 
subsequently induce the down regulation of MPO expres-
sion, which in turn likely decreases the enzyme levels [21].
In the present study, we investigated the association 
of –463G>A polymorphism and MPO levels but we did not 
observe any significant difference between MPO genoty-
pes and patients. A study carried out by Duzguncınar et 
al., (2008) [22] showed that MPO levels were elevated in 
Turkish patients with CAD and this increase is correlated 
Table 6. Haplotype association of myeloperoxidase (MPO) –463G>A and –129G>A genotype and allelic frequencies in patients and con-
trols (n = 400)
SNP 1  
(–463G>A)
SNP 2  
(–129G>A)
Frequency OR (95%CI) P value
G G 0.517 1 –
A G 0.214 0.64 (0.420–0.960) 0.032*
G A 0.208 0.91 (0.600–1.380) 0.650
A A 0.062 1.77 (0.850–3.690) 0.130
*p value < 0.05; SNP — single nucleotide polymorphisms; OR — odds ratio; CI — confidence interval
Figure 1. Linkage disequilibrium pattern of the genomic region in 
chromosome 17q located between single nucleotide polymor - 
p hisms (SNP) –463G>A and –129G>A; MPO — myeloperoxidase
with extent and severity of atherosclerosis. In our study we 
observed that increased MPO levels in CAD cases when 
compared with controls as similar to previous studies.
Several studies have reported the association of 
–463G>A and –129G>A polymorphism with CAD. However 
these results may vary depending upon the ethnicity of the 
study population. Therefore we evaluated the association 
between –463G>A and –129G>A promoter polymorphisms 
of the MPO gene with risk of CAD in South Indian popu-
lation and this is the first study reporting the variation in 
association with CAD in South Indian cohorts.
Our study is in coherence with investigation by Nikpoor 
et al., in French Canadian population (2001) [23] who 
reported recessive allele “A” being statistically associated 
with less probability of developing CAD. Another study 
carried out by Zhang et al., (2008) [24] suggested that 
the risk of premature CAD was significantly reduced with 
–463AA genotype and the similar results were observed 
in the present study.
In a recent meta-analysis carried out by Chen et al., 
(2013) [25] including 3,449 cases and 3,082 controls 
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from 15 case-control studies including both Asians and 
Caucasians revealed strong association of MPO –463G>A 
polymorphism with CAD. The pooled OR for genotypes AA 
vs AG + GG were significantly associated with reduced 
risk of CAD (OR = 0.38, 95% CI [0.26–0.57], p = 0.001) 
and this study suggested that the MPO –463G>A variant 
is associated with decreased risk of CAD. In the present 
study we found that there was no significant association 
between MPO –129G>A gene polymorphism and risk of 
CAD. Our study is supported by observation that pooled 
OR for genotypes GG vs AA + AG in MPO –129G>A gene 
polymorphism, was not significantly associated (OR = 0.91; 
95% CI [0.74–1.10], p = 0.32) [24].
According to Nikpoor et al., (2001) [23] MPO gene 
–463G/A polymorphism is related with changes in lipid 
levels and it is involved in the oxidation of low density 
lipoprotein, the high levels of MPO increasing the brit-
tleness of artery plaque, there by converting the plaque 
from stable to unstable state, thus increasing the risk of 
Acute coronary syndrome. The MPO –463A allele could 
interfere with the binding sites of sp1 transcription factor, 
by reducing the level of MPO gene expression and its role 
in plaque formation, thus having a definite impact on risk 
of CAD. Meanwhile MPO may promote the oxidation of 
HDL-C and affect the reverse cholesterol transport, thereby 
interfering in the development of disease. In the present 
study family history, smoking, alcohol, TC, LDL-C and TG 
are independent predictors for early onset of CAD, thus 
conforming they are traditional risk factors contributing 
independently to disease.
Conclusion
In summary, in the present study we found that MPO levels 
were increasing in CAD but there was no effect of –463G>A 
gene polymorphism on MPO levels and in our study there 
was significant association of –463G>A recessive allele 
as well as genotype in the clinical condition of CAD. The 
presence of recessive allele offers a benign effect by down 
regulating the levels of circulatory MPO enzyme thereby 
implying lower oxidation of LDL and reducing atheroscle-
rotic events occurring CAD. The haplotype analysis of our 
study revealed that SNP 1 of AA genotype and SNP 2 of GG 
genotype has a protective role in clinical condition of CAD. 
However there was no significant association observed 
for –129G>A polymorphism and CAD pathophysiology. 
However, there is no strong LD between the two promoter 
polymorphisms in both patients and controls. The study 
underscores the importance of MPO polymorphism and 
its associated down regulation as a protective confounder 
in atheroprotection in CAD.
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Streszczenie
Wstęp. Badanie przeprowadzono w celu oceny potencjalnych zależności między polimorfizmem genów mieloperoksyda-
zy (MPO) –463G>A i –129G>A oraz stężeniami MPO w osoczu a ryzykiem rozwoju choroby wieńcowej (CAD).
Materiał i metody. Do badania włączono 200 chorych z potwierdzoną w badaniu angiograficznym CAD oraz 200 zdro-
wych osób dobranych pod względem wieku, płci i pochodzenia etnicznego tworzących grupę kontrolną. Stężenie MPO 
w osoczu mierzono metodą immunoabsorpcyjną (ELISA), a do genotypowania zastosowano technikę PCR-RFLP.
Wyniki. Stężenia MPO były istotnie wyższe u chorych z CAD niż u osób z grupy kontrolnej (p < 0,04), jednak nie stwierdzo-
no, by polimorfizm genu –463G>A miał istotny wpływ na stężenie tego enzymu. Zaobserwowano natomiast statystycznie 
istotny związek polimorfizmu genu –463G>A z występowaniem CAD. Recesywny genotyp „AA” w obrębie promotora 
–463 występował znacznie rzadziej u chorych z CAD (4%) niż w grupie kontrolnej (11%) (iloraz szans [OR] = 0,3371; 
95-procentowy przedział ufności [CI] 0,1463–0,7766; p = 0,012). Jednak nie stwierdzono istotnych zależności między 
polimorfizmem genu –129G>A a CAD, a ponadto dodatkowa analiza haplotypu wykazała, że polimorfizmy pojedynczego 
nukleotydu (SNP) (SNP 1 genotypu AA oraz SNP 2 genotypu GG) miały istotny ochronny wpływ na wystąpienie choroby 
[OR = 0,64; 95% CI 0,42–0,96; p = 0,032].
Wnioski. Wyniki badania dowiodły, że polimorfizm –463G>A genu MPO ma ochronny wpływ na występowanie CAD przez 
obniżenie osoczowego stężenia MPO — enzymu nasilającego rozwój zmian miażdżycowych u chorych z CAD.
Słowa kluczowe: wczesny początek choroby wieńcowej, mieloperoksydaza, polimorfizm genów, Atheros
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